PeptiSystems provides the next generation synthesis instruments for peptide and oligonucleotide synthesis. For decades, the industry standard for synthesizing peptides has been Batch Reactor technology. It is expensive, time consuming, generates a lot of chemical waste and CO2 emissions. It is also challenging to increase from small scale to large scale manufacturing.
PeptiSystems instruments utilize Continuous Flow (CF) technology instead together with a patentable innovation developed by PeptiSystems. This reduces synthesis time by 10x (from months to days), increases automation, reduces CO2 emissions by 50%, saves significantly on manufacturing cost and facilitates process development from small scale to large scale manufacturing. PeptiSystems founders earlier worked at General Electric Healthcare (GEHC) developing prototypes after such instruments were requested from some of the largest peptide manufacturers in the world, but the project was terminated when GEHC reorganized to focus on their core business. The team then started PeptiSystems and has unique know-how in developing hardware and software for this application, as well as the chemical expertise and creativity necessary to succeed.
PeptiSystems will have a final commercial instrument ready before the end of 2019. We have already received an customer commitment for a large scale process instrument worth 750 kUR. We are looking for investors!